Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Tobii AB (publ) in connection with its rights issue
Mandate

Vinge has advised Tobii AB (publ) in connection with its rights issue

April 03, 2024 Capital Markets and Public M&A

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary shares which will provide Tobii with issue proceeds of approximately SEK 301 million before deduction of transaction costs.

The new ordinary shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 15 April 2024. Tobii develops technology within eye tracking and attention computing which understands human attention and intent. Tobii’s eye tracking solutions are used by thousands of enterprises, universities and research institutes around the globe. The company's ordinary shares are listed on Nasdaq Stockholm.

 

Vinge’s team consisted primarily of Jesper Schönbeck, Rikard Lindahl, Amanda Knutsson, Joel Magnusson, Oskar Nilsson, Lorin Arabi, Elias Kröger, Lovisa Jonassen och William Carlberg Johansson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025